News | September 13, 2021
Boehringer Ingelheim and Twist Bioscience ink antibody discovery collaboration
Research collaboration covers multiple antibody research programs
Research collaboration covers multiple antibody research programs
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The company said Revital NXT is India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Subscribe To Our Newsletter & Stay Updated
